Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
48 studies found for:    "Li Fraumeni syndrome"
Show Display Options
Rank Status Study
21 Completed Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer
Condition: Breast Cancer
Interventions: Biological: filgrastim;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: epirubicin hydrochloride;   Drug: fluorouracil;   Genetic: microarray analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: biopsy;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy;   Radiation: radiation therapy
22 Completed A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
Condition: Ovarian Cancer
Interventions: Drug: MK-1775;   Drug: Placebo;   Drug: paclitaxel;   Drug: carboplatin
23 Terminated Wild Type p53 Adenovirus for Oral Premalignancies
Condition: Mouth Cancer
Intervention: Genetic: INGN 201
24 Completed Gene Therapy in Treating Patients With Recurrent Malignant Gliomas
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: Ad5CMV-p53 gene;   Procedure: conventional surgery
25 Recruiting Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Procedure: Blood specimen
26 Completed Genetic Polymorphisms Associated With Cigarette Smoking and Risk of Graves’ Disease
Condition: Graves' Disease
Intervention:
27 Unknown  Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Peritoneal Cavity Cancer
Intervention: Biological: Ad5CMV-p53 gene
28 Recruiting Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma
Condition: GLIOBLASTOMA
Interventions: Genetic: SGT-53;   Drug: Temozolomide
29 Recruiting Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
Condition: Metastatic Pancreatic Cancer
Interventions: Genetic: SGT-53;   Drug: nab-paclitaxel;   Drug: Gemcitabine
30 Recruiting p53 and Response to Preoperative Radiotherapy for T2 and T3
Condition: Rectal Cancer
Intervention: Radiation: preoperative short course radiation
31 Unknown  Duct Endoscopy in Assessing Cellular Atypia in the Breast Duct Fluid of Women With a Genetic Risk for Breast Cancer
Condition: Breast Cancer
Interventions: Genetic: cytogenetic analysis;   Genetic: proteomic profiling;   Other: cytology specimen collection procedure;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: breast duct lavage
32 Recruiting ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
Conditions: Solid Tumor;   Lymphoma;   Peripheral T-Cell Lymphoma
Intervention: Drug: ALRN-6924
33 Completed Chemotherapy Followed By Vaccine Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Biological: Autologous dendritic cell-adenovirus p53 vaccine;   Drug: Carboplatin;   Drug: Etoposide
34 Completed Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx
Conditions: Lip and Oral Cavity Cancer;   Oropharyngeal Cancer;   Stage 0 Lip and Oral Cavity Cancer;   Stage 0 Oropharyngeal Cancer;   Tongue Cancer
Interventions: Biological: Ad5CMV-p53 gene;   Other: laboratory biomarker analysis
35 Active, not recruiting
Has Results
To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid
Condition: Small Cell Lung Cancer
Interventions: Drug: Paclitaxel;   Biological: Drug: Ad.p53-DC vaccines;   Drug: All -trans Retinoic Acid (ATRA)
36 Recruiting Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer
Conditions: Stomach Neoplasms;   Stomach Cancer;   Familial Cancer;   Fundic Gland Polyposis;   Li-Fraumeni Syndrome;   Lynch Syndrome;   Peutz-Jeghers Syndrome
Intervention:
37 Recruiting Familial Investigations of Childhood Cancer Predisposition
Conditions: Acute Leukemia;   Adenomatous Polyposis;   Adrenocortical Carcinoma;   AML;   BAP1 Tumor Predisposition Syndrome;   Carney Complex;   Choroid Plexus Carcinoma;   Constitutional Mismatch Repair Deficiency Syndrome;   Diamond-Blackfan Anemia;   DICER1 Syndrome;   Dyskeratosis Congenita;   Emberger Syndrome;   Familial Acute Myeloid Leukaemia;   Familial Adenomatous Polyposis;   Fanconi Anemia;   Familial Cancer;   Familial Wilms Tumor;   Familial Neuroblastoma;   GIST;   Hereditary Breast and Ovarian Cancer;   Hereditary Paraganglioma-Pheochromocytoma Syndrome;   Hodgkin Lymphoma;   Juvenile Polyposis;   Li-Fraumeni Syndrome;   Lynch Syndrome;   MDS;   Melanoma Syndrome;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Neuroblastoma;   Neurofibromatosis Type 1;   Neurofibromatosis Type II;   Nevoid Basal Cell Carcinoma Syndrome;   Non Hodgkin Lymphoma;   Noonan Syndrome and Other Rasopathy;   Overgrowth Syndromes;   Pancreatic Cancer;   Peutz-Jeghers Syndrome;   Pheochromocytoma/Paraganglioma;   PTEN Hamartoma Tumor Syndrome;   Retinoblastoma;   Rhabdoid Tumor Predisposition Syndrome;   Rhabdomyosarcoma;   Rothmund-Thomson Syndrome;   Tuberous Sclerosis;   Von Hippel-Lindau Disease
Intervention:
38 Not yet recruiting P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: PD-L1 Positive;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   TP53 Gene Mutation
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Modified Vaccinia Virus Ankara Vaccine Expressing p53;   Biological: Pembrolizumab
39 Completed P53 in Differentiated Thyroid Cancer
Condition: Thyroid Neoplasms
Intervention:
40 Recruiting Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
Conditions: Adult Solid Neoplasm;   Bladder Carcinoma;   Colon Carcinoma;   Estrogen Receptor Negative;   Head and Neck Squamous Cell Carcinoma;   Hepatocellular Carcinoma;   HER2/Neu Negative;   Melanoma;   Non-Small Cell Lung Carcinoma;   Pancreatic Carcinoma;   Progesterone Receptor Negative;   Rectal Carcinoma;   Renal Cell Carcinoma;   Soft Tissue Sarcoma;   Triple-Negative Breast Carcinoma;   TP53 Gene Mutation;   Unresectable Solid Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Modified Vaccinia Virus Ankara Vaccine Expressing p53;   Biological: Pembrolizumab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-48) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.